

## Notice Under Section 708A (5) of the Corporations Act (ASX Code: ANP)

This notice is given under paragraph (5)e of section 708A of the Corporations Act.

<b>Type</b>	Shares
<b>Class</b>	Ordinary
<b>ASX Code</b>	ANP
<b>Date of Issue</b>	28 January 2022
<b>Number Issued</b>	87,225
<b>Issue price per security:</b>	\$0.24

Antisense Therapeutics Limited gives notice under section 708A(5)e of the *Corporations Act 2001* (Cth) (the “Corporations Act”) that:

1. The abovementioned ordinary shares were issued without disclosure to investors under Part 6D.2 of the *Corporations Act*;
2. As at the date of this notice the Company has complied with:
  - i. The provisions of the Chapter 2M *Corporations Act* as they apply to the Company; and
  - ii. Section 674 *Corporations Act*; and
3. As at the date of this notice there is no “excluded information” (as defined in subsection 708A (7) of the *Corporations Act*) which is required to be disclosed by the Company.

For and on behalf of the Company,  
Kind Regards,



Phillip Hains  
Company Secretary  
Antisense Therapeutics Limited

Dated: 28 January 2022